Abstract
Vacuolar-type ATPases are multicomponent proton pumps involved in the acidification of single membrane intracellular compartments such as endosomes and lysosomes. They couple the hydrolysis of ATP to the translocation of one to two protons across the membrane. Acidification of the lumen of single membrane organelles is a necessary factor for the correct traffic of membranes and cargo to and from the different internal compartments of a cell. Also, V-ATPases are involved in regulation of pH at the cytosol and, possibly, extracellular milieu. The inhibition of V-ATPases has been shown to induce apoptosis and cell cycle arrest in tumour cells and, therefore, chemicals that behave as inhibitors of this kind of proton pumps have been proposed as putative treatment agents against cancer and many have been patented as such. The compounds filed in patents fall into five major types: plecomacrolides, benzolactone enamides, archazolids, chondropsins and indoles. All these have proved to be apoptosis inducers in cell culture and many to be able to reduce xenograft tumor growth in murine models. The present review will summarize their general structure, origin and mechanisms of action and put them in relation to the patents registered so far for the treatment of cancer.
Keywords: V-ATPase, bafilomycin, chondropsin, concanamycin, salicylihalamide
Recent Patents on Anti-Cancer Drug Discovery
Title: Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Volume: 5 Issue: 2
Author(s): Agustin Hernandez, Gloria Serrano, Rosana Herrera-Palau, Jose R. Perez-Castineira and Aurelio Serrano
Affiliation:
Keywords: V-ATPase, bafilomycin, chondropsin, concanamycin, salicylihalamide
Abstract: Vacuolar-type ATPases are multicomponent proton pumps involved in the acidification of single membrane intracellular compartments such as endosomes and lysosomes. They couple the hydrolysis of ATP to the translocation of one to two protons across the membrane. Acidification of the lumen of single membrane organelles is a necessary factor for the correct traffic of membranes and cargo to and from the different internal compartments of a cell. Also, V-ATPases are involved in regulation of pH at the cytosol and, possibly, extracellular milieu. The inhibition of V-ATPases has been shown to induce apoptosis and cell cycle arrest in tumour cells and, therefore, chemicals that behave as inhibitors of this kind of proton pumps have been proposed as putative treatment agents against cancer and many have been patented as such. The compounds filed in patents fall into five major types: plecomacrolides, benzolactone enamides, archazolids, chondropsins and indoles. All these have proved to be apoptosis inducers in cell culture and many to be able to reduce xenograft tumor growth in murine models. The present review will summarize their general structure, origin and mechanisms of action and put them in relation to the patents registered so far for the treatment of cancer.
Export Options
About this article
Cite this article as:
Hernandez Agustin, Serrano Gloria, Herrera-Palau Rosana, Perez-Castineira R. Jose and Serrano Aurelio, Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936216
DOI https://dx.doi.org/10.2174/157489210790936216 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Current Vascular Pharmacology Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation
Current Medicinal Chemistry The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design A Single Center Phase II Study of Continuous Infusion of Low-dose 5- fluorouracil for Heavily Pretreated Patients With Metastatic Colorectal Cancer
Clinical Cancer Drugs Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets Stem Cells for Microenvironmental Modulation and Retinal Regeneration
Current Tissue Engineering (Discontinued) Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Adenoid Cystic Carcinoma of the Breast
Current Medical Imaging Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics A Novel Class of Emerging Anticancer Compounds: Oxyprenylated Secondary Metabolites from Plants and Fungi
Current Medicinal Chemistry Meet Our Regional Editor
Current Bioinformatics The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4
Current Drug Metabolism Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry